Evidence map›Paper›PMID 28362562›Full record

Trial reportJournal of clinical oncology : official journal of the American Society of Clinical Oncology2017

Ten-Year Progression-Free and Overall Survival in Patients With Unresectable or Metastatic GI Stromal Tumors: Long-Term Analysis of the European Organisation for Research and Treatment of Cancer, Italian Sarcoma Group, and Australasian Gastrointestinal Trials Group Intergroup Phase III Randomized Trial on Imatinib at Two Dose Levels.

Paolo G Casali, John Zalcberg, Axel Le Cesne, Peter Reichardt, Jean-Yves Blay, Lars H Lindner, Ian R Judson, Patrick Schöffski, Serge Leyvraz, Antoine Italiano and 14 more

Registry-linked trialAbstract readClinical Trial, Phase IIIMulticenter StudyRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05464875 (A Multicenter Study of Avapritinib Efficacy and Safety of Metastatic or Unresectable Gastrointestinal Stromal Tumors), which is not on this map. Cited by 115 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
115citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05464875 recruitingnot on this mapstarted 2022, after this paper: background citation

A Multicenter Study of Avapritinib Efficacy and Safety of Metastatic or Unresectable Gastrointestinal Stromal Tumors

TypeobservationalSponsorXinhua Zhang, MDRan2022 to 2025Enrolled74ConditionsGastrointestinal Stromal Tumors, Unresectable Solid Tumor, Recurrent Metastatic Malignant Neoplasm
3 · Its place in the literature

Who cites it

115 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Guideline
  2. Pooled it
  3. Trial
  4. KIT and PDGFRA Mutations and Survival of Gastrointestinal Stromal Tumor Patients Treated with Adjuvant Imatinib in a Randomized Trial.Clinical cancer research : an official journal of the American Association for Cancer Research · 2023
    Trial
  5. Trial
  6. Trial
  7. Trial
  8. Phase II Trial of Imatinib Plus Binimetinib in Patients With Treatment-Naive Advanced Gastrointestinal Stromal Tumor.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2022
    Trial
  9. Trial
  10. Trial
  11. Article
  12. Review
  13. Observational
  14. Article
  15. Article
  16. Article
  17. Differential [European journal of nuclear medicine and molecular imaging · 2026
    Article
  18. Article
  19. Article
  20. Article

55 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

24 authors.

Paolo G CasaliPaolo G. Casali, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale Tumori and University of Milan; Elena Fumagalli and Alessandro Gronchi, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale Tumori, Milano, Italy; John Zalcberg, Peter MacCallum Cancer Institute, East Melbourne, Victoria; Dusan Kotasek, Adelaide Cancer Centre, Kurralta Park and University of Adelaide, South Australia, Australia; Axel Le Cesne, Gustave Roussy, Villejuif; Jean-Yves Blay, NetSARC and Site de Recherche Intégrée sur le Cancer de Lyon, Centre Leon Berard, Lyon; Antoine Italiano, Institut Bergonie, Bordeaux, France; Peter Reichardt, HELIOS Klinikum Berlin-Buch, Berlin; Lars H. Lindner, Klinikum der Universitaet München, München; Viktor Grünwald, School Hannover, Hannover, Germany; Ian R. Judson and Winette van der Graaf, Royal Marsden Hospital, London, United Kingdom; Patrick Schöffski, Universitaire Ziekenhuizen Leuven, Campus Gasthuisberg, Leuven; Saskia Litière and Sandrine Marreaud, European Organisation for Research and Treatment of Cancer Headquarters, Brussels, Belgium; Serge Leyvraz, University Hospital, Lausanne, Switzerland; Antonio Lopez Pousa, Hospital De La Santa Creu I Sant Pau, Barcelona, Spain; Stefan Sleijfer and Jaap Verweij, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam; Jan M. Kerst, The Netherlands Cancer Institute, Amsterdam; Pancras Hogendoorn, Leiden University Medical Center, Leiden; Winette van der Graaf, Radboud University, Medical Center Nijmegen, the Netherlands; and Piotr Rutkowski, Maria Sklodowska-Curie Memorial Cancer Centre and Institute of Oncology, Warsaw, Poland.
John ZalcbergPaolo G. Casali, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale Tumori and University of Milan; Elena Fumagalli and Alessandro Gronchi, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale Tumori, Milano, Italy; John Zalcberg, Peter MacCallum Cancer Institute, East Melbourne, Victoria; Dusan Kotasek, Adelaide Cancer Centre, Kurralta Park and University of Adelaide, South Australia, Australia; Axel Le Cesne, Gustave Roussy, Villejuif; Jean-Yves Blay, NetSARC and Site de Recherche Intégrée sur le Cancer de Lyon, Centre Leon Berard, Lyon; Antoine Italiano, Institut Bergonie, Bordeaux, France; Peter Reichardt, HELIOS Klinikum Berlin-Buch, Berlin; Lars H. Lindner, Klinikum der Universitaet München, München; Viktor Grünwald, School Hannover, Hannover, Germany; Ian R. Judson and Winette van der Graaf, Royal Marsden Hospital, London, United Kingdom; Patrick Schöffski, Universitaire Ziekenhuizen Leuven, Campus Gasthuisberg, Leuven; Saskia Litière and Sandrine Marreaud, European Organisation for Research and Treatment of Cancer Headquarters, Brussels, Belgium; Serge Leyvraz, University Hospital, Lausanne, Switzerland; Antonio Lopez Pousa, Hospital De La Santa Creu I Sant Pau, Barcelona, Spain; Stefan Sleijfer and Jaap Verweij, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam; Jan M. Kerst, The Netherlands Cancer Institute, Amsterdam; Pancras Hogendoorn, Leiden University Medical Center, Leiden; Winette van der Graaf, Radboud University, Medical Center Nijmegen, the Netherlands; and Piotr Rutkowski, Maria Sklodowska-Curie Memorial Cancer Centre and Institute of Oncology, Warsaw, Poland.
Axel Le CesnePaolo G. Casali, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale Tumori and University of Milan; Elena Fumagalli and Alessandro Gronchi, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale Tumori, Milano, Italy; John Zalcberg, Peter MacCallum Cancer Institute, East Melbourne, Victoria; Dusan Kotasek, Adelaide Cancer Centre, Kurralta Park and University of Adelaide, South Australia, Australia; Axel Le Cesne, Gustave Roussy, Villejuif; Jean-Yves Blay, NetSARC and Site de Recherche Intégrée sur le Cancer de Lyon, Centre Leon Berard, Lyon; Antoine Italiano, Institut Bergonie, Bordeaux, France; Peter Reichardt, HELIOS Klinikum Berlin-Buch, Berlin; Lars H. Lindner, Klinikum der Universitaet München, München; Viktor Grünwald, School Hannover, Hannover, Germany; Ian R. Judson and Winette van der Graaf, Royal Marsden Hospital, London, United Kingdom; Patrick Schöffski, Universitaire Ziekenhuizen Leuven, Campus Gasthuisberg, Leuven; Saskia Litière and Sandrine Marreaud, European Organisation for Research and Treatment of Cancer Headquarters, Brussels, Belgium; Serge Leyvraz, University Hospital, Lausanne, Switzerland; Antonio Lopez Pousa, Hospital De La Santa Creu I Sant Pau, Barcelona, Spain; Stefan Sleijfer and Jaap Verweij, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam; Jan M. Kerst, The Netherlands Cancer Institute, Amsterdam; Pancras Hogendoorn, Leiden University Medical Center, Leiden; Winette van der Graaf, Radboud University, Medical Center Nijmegen, the Netherlands; and Piotr Rutkowski, Maria Sklodowska-Curie Memorial Cancer Centre and Institute of Oncology, Warsaw, Poland.
Peter ReichardtPaolo G. Casali, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale Tumori and University of Milan; Elena Fumagalli and Alessandro Gronchi, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale Tumori, Milano, Italy; John Zalcberg, Peter MacCallum Cancer Institute, East Melbourne, Victoria; Dusan Kotasek, Adelaide Cancer Centre, Kurralta Park and University of Adelaide, South Australia, Australia; Axel Le Cesne, Gustave Roussy, Villejuif; Jean-Yves Blay, NetSARC and Site de Recherche Intégrée sur le Cancer de Lyon, Centre Leon Berard, Lyon; Antoine Italiano, Institut Bergonie, Bordeaux, France; Peter Reichardt, HELIOS Klinikum Berlin-Buch, Berlin; Lars H. Lindner, Klinikum der Universitaet München, München; Viktor Grünwald, School Hannover, Hannover, Germany; Ian R. Judson and Winette van der Graaf, Royal Marsden Hospital, London, United Kingdom; Patrick Schöffski, Universitaire Ziekenhuizen Leuven, Campus Gasthuisberg, Leuven; Saskia Litière and Sandrine Marreaud, European Organisation for Research and Treatment of Cancer Headquarters, Brussels, Belgium; Serge Leyvraz, University Hospital, Lausanne, Switzerland; Antonio Lopez Pousa, Hospital De La Santa Creu I Sant Pau, Barcelona, Spain; Stefan Sleijfer and Jaap Verweij, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam; Jan M. Kerst, The Netherlands Cancer Institute, Amsterdam; Pancras Hogendoorn, Leiden University Medical Center, Leiden; Winette van der Graaf, Radboud University, Medical Center Nijmegen, the Netherlands; and Piotr Rutkowski, Maria Sklodowska-Curie Memorial Cancer Centre and Institute of Oncology, Warsaw, Poland.
Jean-Yves BlayPaolo G. Casali, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale Tumori and University of Milan; Elena Fumagalli and Alessandro Gronchi, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale Tumori, Milano, Italy; John Zalcberg, Peter MacCallum Cancer Institute, East Melbourne, Victoria; Dusan Kotasek, Adelaide Cancer Centre, Kurralta Park and University of Adelaide, South Australia, Australia; Axel Le Cesne, Gustave Roussy, Villejuif; Jean-Yves Blay, NetSARC and Site de Recherche Intégrée sur le Cancer de Lyon, Centre Leon Berard, Lyon; Antoine Italiano, Institut Bergonie, Bordeaux, France; Peter Reichardt, HELIOS Klinikum Berlin-Buch, Berlin; Lars H. Lindner, Klinikum der Universitaet München, München; Viktor Grünwald, School Hannover, Hannover, Germany; Ian R. Judson and Winette van der Graaf, Royal Marsden Hospital, London, United Kingdom; Patrick Schöffski, Universitaire Ziekenhuizen Leuven, Campus Gasthuisberg, Leuven; Saskia Litière and Sandrine Marreaud, European Organisation for Research and Treatment of Cancer Headquarters, Brussels, Belgium; Serge Leyvraz, University Hospital, Lausanne, Switzerland; Antonio Lopez Pousa, Hospital De La Santa Creu I Sant Pau, Barcelona, Spain; Stefan Sleijfer and Jaap Verweij, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam; Jan M. Kerst, The Netherlands Cancer Institute, Amsterdam; Pancras Hogendoorn, Leiden University Medical Center, Leiden; Winette van der Graaf, Radboud University, Medical Center Nijmegen, the Netherlands; and Piotr Rutkowski, Maria Sklodowska-Curie Memorial Cancer Centre and Institute of Oncology, Warsaw, Poland.
Lars H LindnerPaolo G. Casali, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale Tumori and University of Milan; Elena Fumagalli and Alessandro Gronchi, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale Tumori, Milano, Italy; John Zalcberg, Peter MacCallum Cancer Institute, East Melbourne, Victoria; Dusan Kotasek, Adelaide Cancer Centre, Kurralta Park and University of Adelaide, South Australia, Australia; Axel Le Cesne, Gustave Roussy, Villejuif; Jean-Yves Blay, NetSARC and Site de Recherche Intégrée sur le Cancer de Lyon, Centre Leon Berard, Lyon; Antoine Italiano, Institut Bergonie, Bordeaux, France; Peter Reichardt, HELIOS Klinikum Berlin-Buch, Berlin; Lars H. Lindner, Klinikum der Universitaet München, München; Viktor Grünwald, School Hannover, Hannover, Germany; Ian R. Judson and Winette van der Graaf, Royal Marsden Hospital, London, United Kingdom; Patrick Schöffski, Universitaire Ziekenhuizen Leuven, Campus Gasthuisberg, Leuven; Saskia Litière and Sandrine Marreaud, European Organisation for Research and Treatment of Cancer Headquarters, Brussels, Belgium; Serge Leyvraz, University Hospital, Lausanne, Switzerland; Antonio Lopez Pousa, Hospital De La Santa Creu I Sant Pau, Barcelona, Spain; Stefan Sleijfer and Jaap Verweij, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam; Jan M. Kerst, The Netherlands Cancer Institute, Amsterdam; Pancras Hogendoorn, Leiden University Medical Center, Leiden; Winette van der Graaf, Radboud University, Medical Center Nijmegen, the Netherlands; and Piotr Rutkowski, Maria Sklodowska-Curie Memorial Cancer Centre and Institute of Oncology, Warsaw, Poland.
Ian R JudsonPaolo G. Casali, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale Tumori and University of Milan; Elena Fumagalli and Alessandro Gronchi, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale Tumori, Milano, Italy; John Zalcberg, Peter MacCallum Cancer Institute, East Melbourne, Victoria; Dusan Kotasek, Adelaide Cancer Centre, Kurralta Park and University of Adelaide, South Australia, Australia; Axel Le Cesne, Gustave Roussy, Villejuif; Jean-Yves Blay, NetSARC and Site de Recherche Intégrée sur le Cancer de Lyon, Centre Leon Berard, Lyon; Antoine Italiano, Institut Bergonie, Bordeaux, France; Peter Reichardt, HELIOS Klinikum Berlin-Buch, Berlin; Lars H. Lindner, Klinikum der Universitaet München, München; Viktor Grünwald, School Hannover, Hannover, Germany; Ian R. Judson and Winette van der Graaf, Royal Marsden Hospital, London, United Kingdom; Patrick Schöffski, Universitaire Ziekenhuizen Leuven, Campus Gasthuisberg, Leuven; Saskia Litière and Sandrine Marreaud, European Organisation for Research and Treatment of Cancer Headquarters, Brussels, Belgium; Serge Leyvraz, University Hospital, Lausanne, Switzerland; Antonio Lopez Pousa, Hospital De La Santa Creu I Sant Pau, Barcelona, Spain; Stefan Sleijfer and Jaap Verweij, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam; Jan M. Kerst, The Netherlands Cancer Institute, Amsterdam; Pancras Hogendoorn, Leiden University Medical Center, Leiden; Winette van der Graaf, Radboud University, Medical Center Nijmegen, the Netherlands; and Piotr Rutkowski, Maria Sklodowska-Curie Memorial Cancer Centre and Institute of Oncology, Warsaw, Poland.
Patrick SchöffskiPaolo G. Casali, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale Tumori and University of Milan; Elena Fumagalli and Alessandro Gronchi, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale Tumori, Milano, Italy; John Zalcberg, Peter MacCallum Cancer Institute, East Melbourne, Victoria; Dusan Kotasek, Adelaide Cancer Centre, Kurralta Park and University of Adelaide, South Australia, Australia; Axel Le Cesne, Gustave Roussy, Villejuif; Jean-Yves Blay, NetSARC and Site de Recherche Intégrée sur le Cancer de Lyon, Centre Leon Berard, Lyon; Antoine Italiano, Institut Bergonie, Bordeaux, France; Peter Reichardt, HELIOS Klinikum Berlin-Buch, Berlin; Lars H. Lindner, Klinikum der Universitaet München, München; Viktor Grünwald, School Hannover, Hannover, Germany; Ian R. Judson and Winette van der Graaf, Royal Marsden Hospital, London, United Kingdom; Patrick Schöffski, Universitaire Ziekenhuizen Leuven, Campus Gasthuisberg, Leuven; Saskia Litière and Sandrine Marreaud, European Organisation for Research and Treatment of Cancer Headquarters, Brussels, Belgium; Serge Leyvraz, University Hospital, Lausanne, Switzerland; Antonio Lopez Pousa, Hospital De La Santa Creu I Sant Pau, Barcelona, Spain; Stefan Sleijfer and Jaap Verweij, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam; Jan M. Kerst, The Netherlands Cancer Institute, Amsterdam; Pancras Hogendoorn, Leiden University Medical Center, Leiden; Winette van der Graaf, Radboud University, Medical Center Nijmegen, the Netherlands; and Piotr Rutkowski, Maria Sklodowska-Curie Memorial Cancer Centre and Institute of Oncology, Warsaw, Poland.
Serge LeyvrazPaolo G. Casali, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale Tumori and University of Milan; Elena Fumagalli and Alessandro Gronchi, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale Tumori, Milano, Italy; John Zalcberg, Peter MacCallum Cancer Institute, East Melbourne, Victoria; Dusan Kotasek, Adelaide Cancer Centre, Kurralta Park and University of Adelaide, South Australia, Australia; Axel Le Cesne, Gustave Roussy, Villejuif; Jean-Yves Blay, NetSARC and Site de Recherche Intégrée sur le Cancer de Lyon, Centre Leon Berard, Lyon; Antoine Italiano, Institut Bergonie, Bordeaux, France; Peter Reichardt, HELIOS Klinikum Berlin-Buch, Berlin; Lars H. Lindner, Klinikum der Universitaet München, München; Viktor Grünwald, School Hannover, Hannover, Germany; Ian R. Judson and Winette van der Graaf, Royal Marsden Hospital, London, United Kingdom; Patrick Schöffski, Universitaire Ziekenhuizen Leuven, Campus Gasthuisberg, Leuven; Saskia Litière and Sandrine Marreaud, European Organisation for Research and Treatment of Cancer Headquarters, Brussels, Belgium; Serge Leyvraz, University Hospital, Lausanne, Switzerland; Antonio Lopez Pousa, Hospital De La Santa Creu I Sant Pau, Barcelona, Spain; Stefan Sleijfer and Jaap Verweij, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam; Jan M. Kerst, The Netherlands Cancer Institute, Amsterdam; Pancras Hogendoorn, Leiden University Medical Center, Leiden; Winette van der Graaf, Radboud University, Medical Center Nijmegen, the Netherlands; and Piotr Rutkowski, Maria Sklodowska-Curie Memorial Cancer Centre and Institute of Oncology, Warsaw, Poland.
Antoine ItalianoPaolo G. Casali, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale Tumori and University of Milan; Elena Fumagalli and Alessandro Gronchi, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale Tumori, Milano, Italy; John Zalcberg, Peter MacCallum Cancer Institute, East Melbourne, Victoria; Dusan Kotasek, Adelaide Cancer Centre, Kurralta Park and University of Adelaide, South Australia, Australia; Axel Le Cesne, Gustave Roussy, Villejuif; Jean-Yves Blay, NetSARC and Site de Recherche Intégrée sur le Cancer de Lyon, Centre Leon Berard, Lyon; Antoine Italiano, Institut Bergonie, Bordeaux, France; Peter Reichardt, HELIOS Klinikum Berlin-Buch, Berlin; Lars H. Lindner, Klinikum der Universitaet München, München; Viktor Grünwald, School Hannover, Hannover, Germany; Ian R. Judson and Winette van der Graaf, Royal Marsden Hospital, London, United Kingdom; Patrick Schöffski, Universitaire Ziekenhuizen Leuven, Campus Gasthuisberg, Leuven; Saskia Litière and Sandrine Marreaud, European Organisation for Research and Treatment of Cancer Headquarters, Brussels, Belgium; Serge Leyvraz, University Hospital, Lausanne, Switzerland; Antonio Lopez Pousa, Hospital De La Santa Creu I Sant Pau, Barcelona, Spain; Stefan Sleijfer and Jaap Verweij, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam; Jan M. Kerst, The Netherlands Cancer Institute, Amsterdam; Pancras Hogendoorn, Leiden University Medical Center, Leiden; Winette van der Graaf, Radboud University, Medical Center Nijmegen, the Netherlands; and Piotr Rutkowski, Maria Sklodowska-Curie Memorial Cancer Centre and Institute of Oncology, Warsaw, Poland.
Viktor GrünwaldPaolo G. Casali, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale Tumori and University of Milan; Elena Fumagalli and Alessandro Gronchi, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale Tumori, Milano, Italy; John Zalcberg, Peter MacCallum Cancer Institute, East Melbourne, Victoria; Dusan Kotasek, Adelaide Cancer Centre, Kurralta Park and University of Adelaide, South Australia, Australia; Axel Le Cesne, Gustave Roussy, Villejuif; Jean-Yves Blay, NetSARC and Site de Recherche Intégrée sur le Cancer de Lyon, Centre Leon Berard, Lyon; Antoine Italiano, Institut Bergonie, Bordeaux, France; Peter Reichardt, HELIOS Klinikum Berlin-Buch, Berlin; Lars H. Lindner, Klinikum der Universitaet München, München; Viktor Grünwald, School Hannover, Hannover, Germany; Ian R. Judson and Winette van der Graaf, Royal Marsden Hospital, London, United Kingdom; Patrick Schöffski, Universitaire Ziekenhuizen Leuven, Campus Gasthuisberg, Leuven; Saskia Litière and Sandrine Marreaud, European Organisation for Research and Treatment of Cancer Headquarters, Brussels, Belgium; Serge Leyvraz, University Hospital, Lausanne, Switzerland; Antonio Lopez Pousa, Hospital De La Santa Creu I Sant Pau, Barcelona, Spain; Stefan Sleijfer and Jaap Verweij, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam; Jan M. Kerst, The Netherlands Cancer Institute, Amsterdam; Pancras Hogendoorn, Leiden University Medical Center, Leiden; Winette van der Graaf, Radboud University, Medical Center Nijmegen, the Netherlands; and Piotr Rutkowski, Maria Sklodowska-Curie Memorial Cancer Centre and Institute of Oncology, Warsaw, Poland.
Antonio Lopez PousaPaolo G. Casali, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale Tumori and University of Milan; Elena Fumagalli and Alessandro Gronchi, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale Tumori, Milano, Italy; John Zalcberg, Peter MacCallum Cancer Institute, East Melbourne, Victoria; Dusan Kotasek, Adelaide Cancer Centre, Kurralta Park and University of Adelaide, South Australia, Australia; Axel Le Cesne, Gustave Roussy, Villejuif; Jean-Yves Blay, NetSARC and Site de Recherche Intégrée sur le Cancer de Lyon, Centre Leon Berard, Lyon; Antoine Italiano, Institut Bergonie, Bordeaux, France; Peter Reichardt, HELIOS Klinikum Berlin-Buch, Berlin; Lars H. Lindner, Klinikum der Universitaet München, München; Viktor Grünwald, School Hannover, Hannover, Germany; Ian R. Judson and Winette van der Graaf, Royal Marsden Hospital, London, United Kingdom; Patrick Schöffski, Universitaire Ziekenhuizen Leuven, Campus Gasthuisberg, Leuven; Saskia Litière and Sandrine Marreaud, European Organisation for Research and Treatment of Cancer Headquarters, Brussels, Belgium; Serge Leyvraz, University Hospital, Lausanne, Switzerland; Antonio Lopez Pousa, Hospital De La Santa Creu I Sant Pau, Barcelona, Spain; Stefan Sleijfer and Jaap Verweij, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam; Jan M. Kerst, The Netherlands Cancer Institute, Amsterdam; Pancras Hogendoorn, Leiden University Medical Center, Leiden; Winette van der Graaf, Radboud University, Medical Center Nijmegen, the Netherlands; and Piotr Rutkowski, Maria Sklodowska-Curie Memorial Cancer Centre and Institute of Oncology, Warsaw, Poland.
Dusan KotasekPaolo G. Casali, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale Tumori and University of Milan; Elena Fumagalli and Alessandro Gronchi, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale Tumori, Milano, Italy; John Zalcberg, Peter MacCallum Cancer Institute, East Melbourne, Victoria; Dusan Kotasek, Adelaide Cancer Centre, Kurralta Park and University of Adelaide, South Australia, Australia; Axel Le Cesne, Gustave Roussy, Villejuif; Jean-Yves Blay, NetSARC and Site de Recherche Intégrée sur le Cancer de Lyon, Centre Leon Berard, Lyon; Antoine Italiano, Institut Bergonie, Bordeaux, France; Peter Reichardt, HELIOS Klinikum Berlin-Buch, Berlin; Lars H. Lindner, Klinikum der Universitaet München, München; Viktor Grünwald, School Hannover, Hannover, Germany; Ian R. Judson and Winette van der Graaf, Royal Marsden Hospital, London, United Kingdom; Patrick Schöffski, Universitaire Ziekenhuizen Leuven, Campus Gasthuisberg, Leuven; Saskia Litière and Sandrine Marreaud, European Organisation for Research and Treatment of Cancer Headquarters, Brussels, Belgium; Serge Leyvraz, University Hospital, Lausanne, Switzerland; Antonio Lopez Pousa, Hospital De La Santa Creu I Sant Pau, Barcelona, Spain; Stefan Sleijfer and Jaap Verweij, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam; Jan M. Kerst, The Netherlands Cancer Institute, Amsterdam; Pancras Hogendoorn, Leiden University Medical Center, Leiden; Winette van der Graaf, Radboud University, Medical Center Nijmegen, the Netherlands; and Piotr Rutkowski, Maria Sklodowska-Curie Memorial Cancer Centre and Institute of Oncology, Warsaw, Poland.
Stefan SleijferPaolo G. Casali, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale Tumori and University of Milan; Elena Fumagalli and Alessandro Gronchi, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale Tumori, Milano, Italy; John Zalcberg, Peter MacCallum Cancer Institute, East Melbourne, Victoria; Dusan Kotasek, Adelaide Cancer Centre, Kurralta Park and University of Adelaide, South Australia, Australia; Axel Le Cesne, Gustave Roussy, Villejuif; Jean-Yves Blay, NetSARC and Site de Recherche Intégrée sur le Cancer de Lyon, Centre Leon Berard, Lyon; Antoine Italiano, Institut Bergonie, Bordeaux, France; Peter Reichardt, HELIOS Klinikum Berlin-Buch, Berlin; Lars H. Lindner, Klinikum der Universitaet München, München; Viktor Grünwald, School Hannover, Hannover, Germany; Ian R. Judson and Winette van der Graaf, Royal Marsden Hospital, London, United Kingdom; Patrick Schöffski, Universitaire Ziekenhuizen Leuven, Campus Gasthuisberg, Leuven; Saskia Litière and Sandrine Marreaud, European Organisation for Research and Treatment of Cancer Headquarters, Brussels, Belgium; Serge Leyvraz, University Hospital, Lausanne, Switzerland; Antonio Lopez Pousa, Hospital De La Santa Creu I Sant Pau, Barcelona, Spain; Stefan Sleijfer and Jaap Verweij, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam; Jan M. Kerst, The Netherlands Cancer Institute, Amsterdam; Pancras Hogendoorn, Leiden University Medical Center, Leiden; Winette van der Graaf, Radboud University, Medical Center Nijmegen, the Netherlands; and Piotr Rutkowski, Maria Sklodowska-Curie Memorial Cancer Centre and Institute of Oncology, Warsaw, Poland.
Jan M KerstPaolo G. Casali, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale Tumori and University of Milan; Elena Fumagalli and Alessandro Gronchi, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale Tumori, Milano, Italy; John Zalcberg, Peter MacCallum Cancer Institute, East Melbourne, Victoria; Dusan Kotasek, Adelaide Cancer Centre, Kurralta Park and University of Adelaide, South Australia, Australia; Axel Le Cesne, Gustave Roussy, Villejuif; Jean-Yves Blay, NetSARC and Site de Recherche Intégrée sur le Cancer de Lyon, Centre Leon Berard, Lyon; Antoine Italiano, Institut Bergonie, Bordeaux, France; Peter Reichardt, HELIOS Klinikum Berlin-Buch, Berlin; Lars H. Lindner, Klinikum der Universitaet München, München; Viktor Grünwald, School Hannover, Hannover, Germany; Ian R. Judson and Winette van der Graaf, Royal Marsden Hospital, London, United Kingdom; Patrick Schöffski, Universitaire Ziekenhuizen Leuven, Campus Gasthuisberg, Leuven; Saskia Litière and Sandrine Marreaud, European Organisation for Research and Treatment of Cancer Headquarters, Brussels, Belgium; Serge Leyvraz, University Hospital, Lausanne, Switzerland; Antonio Lopez Pousa, Hospital De La Santa Creu I Sant Pau, Barcelona, Spain; Stefan Sleijfer and Jaap Verweij, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam; Jan M. Kerst, The Netherlands Cancer Institute, Amsterdam; Pancras Hogendoorn, Leiden University Medical Center, Leiden; Winette van der Graaf, Radboud University, Medical Center Nijmegen, the Netherlands; and Piotr Rutkowski, Maria Sklodowska-Curie Memorial Cancer Centre and Institute of Oncology, Warsaw, Poland.
Piotr RutkowskiPaolo G. Casali, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale Tumori and University of Milan; Elena Fumagalli and Alessandro Gronchi, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale Tumori, Milano, Italy; John Zalcberg, Peter MacCallum Cancer Institute, East Melbourne, Victoria; Dusan Kotasek, Adelaide Cancer Centre, Kurralta Park and University of Adelaide, South Australia, Australia; Axel Le Cesne, Gustave Roussy, Villejuif; Jean-Yves Blay, NetSARC and Site de Recherche Intégrée sur le Cancer de Lyon, Centre Leon Berard, Lyon; Antoine Italiano, Institut Bergonie, Bordeaux, France; Peter Reichardt, HELIOS Klinikum Berlin-Buch, Berlin; Lars H. Lindner, Klinikum der Universitaet München, München; Viktor Grünwald, School Hannover, Hannover, Germany; Ian R. Judson and Winette van der Graaf, Royal Marsden Hospital, London, United Kingdom; Patrick Schöffski, Universitaire Ziekenhuizen Leuven, Campus Gasthuisberg, Leuven; Saskia Litière and Sandrine Marreaud, European Organisation for Research and Treatment of Cancer Headquarters, Brussels, Belgium; Serge Leyvraz, University Hospital, Lausanne, Switzerland; Antonio Lopez Pousa, Hospital De La Santa Creu I Sant Pau, Barcelona, Spain; Stefan Sleijfer and Jaap Verweij, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam; Jan M. Kerst, The Netherlands Cancer Institute, Amsterdam; Pancras Hogendoorn, Leiden University Medical Center, Leiden; Winette van der Graaf, Radboud University, Medical Center Nijmegen, the Netherlands; and Piotr Rutkowski, Maria Sklodowska-Curie Memorial Cancer Centre and Institute of Oncology, Warsaw, Poland.
Elena FumagalliPaolo G. Casali, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale Tumori and University of Milan; Elena Fumagalli and Alessandro Gronchi, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale Tumori, Milano, Italy; John Zalcberg, Peter MacCallum Cancer Institute, East Melbourne, Victoria; Dusan Kotasek, Adelaide Cancer Centre, Kurralta Park and University of Adelaide, South Australia, Australia; Axel Le Cesne, Gustave Roussy, Villejuif; Jean-Yves Blay, NetSARC and Site de Recherche Intégrée sur le Cancer de Lyon, Centre Leon Berard, Lyon; Antoine Italiano, Institut Bergonie, Bordeaux, France; Peter Reichardt, HELIOS Klinikum Berlin-Buch, Berlin; Lars H. Lindner, Klinikum der Universitaet München, München; Viktor Grünwald, School Hannover, Hannover, Germany; Ian R. Judson and Winette van der Graaf, Royal Marsden Hospital, London, United Kingdom; Patrick Schöffski, Universitaire Ziekenhuizen Leuven, Campus Gasthuisberg, Leuven; Saskia Litière and Sandrine Marreaud, European Organisation for Research and Treatment of Cancer Headquarters, Brussels, Belgium; Serge Leyvraz, University Hospital, Lausanne, Switzerland; Antonio Lopez Pousa, Hospital De La Santa Creu I Sant Pau, Barcelona, Spain; Stefan Sleijfer and Jaap Verweij, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam; Jan M. Kerst, The Netherlands Cancer Institute, Amsterdam; Pancras Hogendoorn, Leiden University Medical Center, Leiden; Winette van der Graaf, Radboud University, Medical Center Nijmegen, the Netherlands; and Piotr Rutkowski, Maria Sklodowska-Curie Memorial Cancer Centre and Institute of Oncology, Warsaw, Poland.
Pancras HogendoornPaolo G. Casali, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale Tumori and University of Milan; Elena Fumagalli and Alessandro Gronchi, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale Tumori, Milano, Italy; John Zalcberg, Peter MacCallum Cancer Institute, East Melbourne, Victoria; Dusan Kotasek, Adelaide Cancer Centre, Kurralta Park and University of Adelaide, South Australia, Australia; Axel Le Cesne, Gustave Roussy, Villejuif; Jean-Yves Blay, NetSARC and Site de Recherche Intégrée sur le Cancer de Lyon, Centre Leon Berard, Lyon; Antoine Italiano, Institut Bergonie, Bordeaux, France; Peter Reichardt, HELIOS Klinikum Berlin-Buch, Berlin; Lars H. Lindner, Klinikum der Universitaet München, München; Viktor Grünwald, School Hannover, Hannover, Germany; Ian R. Judson and Winette van der Graaf, Royal Marsden Hospital, London, United Kingdom; Patrick Schöffski, Universitaire Ziekenhuizen Leuven, Campus Gasthuisberg, Leuven; Saskia Litière and Sandrine Marreaud, European Organisation for Research and Treatment of Cancer Headquarters, Brussels, Belgium; Serge Leyvraz, University Hospital, Lausanne, Switzerland; Antonio Lopez Pousa, Hospital De La Santa Creu I Sant Pau, Barcelona, Spain; Stefan Sleijfer and Jaap Verweij, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam; Jan M. Kerst, The Netherlands Cancer Institute, Amsterdam; Pancras Hogendoorn, Leiden University Medical Center, Leiden; Winette van der Graaf, Radboud University, Medical Center Nijmegen, the Netherlands; and Piotr Rutkowski, Maria Sklodowska-Curie Memorial Cancer Centre and Institute of Oncology, Warsaw, Poland.
Saskia LitièrePaolo G. Casali, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale Tumori and University of Milan; Elena Fumagalli and Alessandro Gronchi, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale Tumori, Milano, Italy; John Zalcberg, Peter MacCallum Cancer Institute, East Melbourne, Victoria; Dusan Kotasek, Adelaide Cancer Centre, Kurralta Park and University of Adelaide, South Australia, Australia; Axel Le Cesne, Gustave Roussy, Villejuif; Jean-Yves Blay, NetSARC and Site de Recherche Intégrée sur le Cancer de Lyon, Centre Leon Berard, Lyon; Antoine Italiano, Institut Bergonie, Bordeaux, France; Peter Reichardt, HELIOS Klinikum Berlin-Buch, Berlin; Lars H. Lindner, Klinikum der Universitaet München, München; Viktor Grünwald, School Hannover, Hannover, Germany; Ian R. Judson and Winette van der Graaf, Royal Marsden Hospital, London, United Kingdom; Patrick Schöffski, Universitaire Ziekenhuizen Leuven, Campus Gasthuisberg, Leuven; Saskia Litière and Sandrine Marreaud, European Organisation for Research and Treatment of Cancer Headquarters, Brussels, Belgium; Serge Leyvraz, University Hospital, Lausanne, Switzerland; Antonio Lopez Pousa, Hospital De La Santa Creu I Sant Pau, Barcelona, Spain; Stefan Sleijfer and Jaap Verweij, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam; Jan M. Kerst, The Netherlands Cancer Institute, Amsterdam; Pancras Hogendoorn, Leiden University Medical Center, Leiden; Winette van der Graaf, Radboud University, Medical Center Nijmegen, the Netherlands; and Piotr Rutkowski, Maria Sklodowska-Curie Memorial Cancer Centre and Institute of Oncology, Warsaw, Poland.
Sandrine MarreaudPaolo G. Casali, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale Tumori and University of Milan; Elena Fumagalli and Alessandro Gronchi, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale Tumori, Milano, Italy; John Zalcberg, Peter MacCallum Cancer Institute, East Melbourne, Victoria; Dusan Kotasek, Adelaide Cancer Centre, Kurralta Park and University of Adelaide, South Australia, Australia; Axel Le Cesne, Gustave Roussy, Villejuif; Jean-Yves Blay, NetSARC and Site de Recherche Intégrée sur le Cancer de Lyon, Centre Leon Berard, Lyon; Antoine Italiano, Institut Bergonie, Bordeaux, France; Peter Reichardt, HELIOS Klinikum Berlin-Buch, Berlin; Lars H. Lindner, Klinikum der Universitaet München, München; Viktor Grünwald, School Hannover, Hannover, Germany; Ian R. Judson and Winette van der Graaf, Royal Marsden Hospital, London, United Kingdom; Patrick Schöffski, Universitaire Ziekenhuizen Leuven, Campus Gasthuisberg, Leuven; Saskia Litière and Sandrine Marreaud, European Organisation for Research and Treatment of Cancer Headquarters, Brussels, Belgium; Serge Leyvraz, University Hospital, Lausanne, Switzerland; Antonio Lopez Pousa, Hospital De La Santa Creu I Sant Pau, Barcelona, Spain; Stefan Sleijfer and Jaap Verweij, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam; Jan M. Kerst, The Netherlands Cancer Institute, Amsterdam; Pancras Hogendoorn, Leiden University Medical Center, Leiden; Winette van der Graaf, Radboud University, Medical Center Nijmegen, the Netherlands; and Piotr Rutkowski, Maria Sklodowska-Curie Memorial Cancer Centre and Institute of Oncology, Warsaw, Poland.
Winette van der GraafPaolo G. Casali, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale Tumori and University of Milan; Elena Fumagalli and Alessandro Gronchi, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale Tumori, Milano, Italy; John Zalcberg, Peter MacCallum Cancer Institute, East Melbourne, Victoria; Dusan Kotasek, Adelaide Cancer Centre, Kurralta Park and University of Adelaide, South Australia, Australia; Axel Le Cesne, Gustave Roussy, Villejuif; Jean-Yves Blay, NetSARC and Site de Recherche Intégrée sur le Cancer de Lyon, Centre Leon Berard, Lyon; Antoine Italiano, Institut Bergonie, Bordeaux, France; Peter Reichardt, HELIOS Klinikum Berlin-Buch, Berlin; Lars H. Lindner, Klinikum der Universitaet München, München; Viktor Grünwald, School Hannover, Hannover, Germany; Ian R. Judson and Winette van der Graaf, Royal Marsden Hospital, London, United Kingdom; Patrick Schöffski, Universitaire Ziekenhuizen Leuven, Campus Gasthuisberg, Leuven; Saskia Litière and Sandrine Marreaud, European Organisation for Research and Treatment of Cancer Headquarters, Brussels, Belgium; Serge Leyvraz, University Hospital, Lausanne, Switzerland; Antonio Lopez Pousa, Hospital De La Santa Creu I Sant Pau, Barcelona, Spain; Stefan Sleijfer and Jaap Verweij, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam; Jan M. Kerst, The Netherlands Cancer Institute, Amsterdam; Pancras Hogendoorn, Leiden University Medical Center, Leiden; Winette van der Graaf, Radboud University, Medical Center Nijmegen, the Netherlands; and Piotr Rutkowski, Maria Sklodowska-Curie Memorial Cancer Centre and Institute of Oncology, Warsaw, Poland.
Alessandro GronchiPaolo G. Casali, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale Tumori and University of Milan; Elena Fumagalli and Alessandro Gronchi, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale Tumori, Milano, Italy; John Zalcberg, Peter MacCallum Cancer Institute, East Melbourne, Victoria; Dusan Kotasek, Adelaide Cancer Centre, Kurralta Park and University of Adelaide, South Australia, Australia; Axel Le Cesne, Gustave Roussy, Villejuif; Jean-Yves Blay, NetSARC and Site de Recherche Intégrée sur le Cancer de Lyon, Centre Leon Berard, Lyon; Antoine Italiano, Institut Bergonie, Bordeaux, France; Peter Reichardt, HELIOS Klinikum Berlin-Buch, Berlin; Lars H. Lindner, Klinikum der Universitaet München, München; Viktor Grünwald, School Hannover, Hannover, Germany; Ian R. Judson and Winette van der Graaf, Royal Marsden Hospital, London, United Kingdom; Patrick Schöffski, Universitaire Ziekenhuizen Leuven, Campus Gasthuisberg, Leuven; Saskia Litière and Sandrine Marreaud, European Organisation for Research and Treatment of Cancer Headquarters, Brussels, Belgium; Serge Leyvraz, University Hospital, Lausanne, Switzerland; Antonio Lopez Pousa, Hospital De La Santa Creu I Sant Pau, Barcelona, Spain; Stefan Sleijfer and Jaap Verweij, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam; Jan M. Kerst, The Netherlands Cancer Institute, Amsterdam; Pancras Hogendoorn, Leiden University Medical Center, Leiden; Winette van der Graaf, Radboud University, Medical Center Nijmegen, the Netherlands; and Piotr Rutkowski, Maria Sklodowska-Curie Memorial Cancer Centre and Institute of Oncology, Warsaw, Poland.
Jaap VerweijPaolo G. Casali, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale Tumori and University of Milan; Elena Fumagalli and Alessandro Gronchi, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale Tumori, Milano, Italy; John Zalcberg, Peter MacCallum Cancer Institute, East Melbourne, Victoria; Dusan Kotasek, Adelaide Cancer Centre, Kurralta Park and University of Adelaide, South Australia, Australia; Axel Le Cesne, Gustave Roussy, Villejuif; Jean-Yves Blay, NetSARC and Site de Recherche Intégrée sur le Cancer de Lyon, Centre Leon Berard, Lyon; Antoine Italiano, Institut Bergonie, Bordeaux, France; Peter Reichardt, HELIOS Klinikum Berlin-Buch, Berlin; Lars H. Lindner, Klinikum der Universitaet München, München; Viktor Grünwald, School Hannover, Hannover, Germany; Ian R. Judson and Winette van der Graaf, Royal Marsden Hospital, London, United Kingdom; Patrick Schöffski, Universitaire Ziekenhuizen Leuven, Campus Gasthuisberg, Leuven; Saskia Litière and Sandrine Marreaud, European Organisation for Research and Treatment of Cancer Headquarters, Brussels, Belgium; Serge Leyvraz, University Hospital, Lausanne, Switzerland; Antonio Lopez Pousa, Hospital De La Santa Creu I Sant Pau, Barcelona, Spain; Stefan Sleijfer and Jaap Verweij, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam; Jan M. Kerst, The Netherlands Cancer Institute, Amsterdam; Pancras Hogendoorn, Leiden University Medical Center, Leiden; Winette van der Graaf, Radboud University, Medical Center Nijmegen, the Netherlands; and Piotr Rutkowski, Maria Sklodowska-Curie Memorial Cancer Centre and Institute of Oncology, Warsaw, Poland.
European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group, Italian Sarcoma Group, and Australasian Gastrointestinal Trials Group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose To report on the long-term results of a randomized trial comparing a standard dose (400 mg/d) versus a higher dose (800 mg/d) of imatinib in patients with metastatic or locally advanced GI stromal tumors (GISTs). Patients and Methods Eligible patients with advanced CD117-positive GIST from 56 institutions in 13 countries were randomly assigned to receive either imatinib 400 mg or 800 mg daily. Patients on the 400-mg arm were allowed to cross over to 800 mg upon progression. Results Between February 2001 and February 2002, 946 patients were accrued. Median age was 60 years (range, 18 to 91 years). Median follow-up time was 10.9 years. Median progression-free survival times were 1.7 and 2.0 years in the 400- and 800-mg arms, respectively (hazard ratio, 0.91; P = .18), and median overall survival time was 3.9 years in both treatment arms. The estimated 10-year progression-free survival rates were 9.5% and 9.2% for the 400- and 800-mg arms, respectively, and the estimated 10-year overall survival rates were 19.4% and 21.5%, respectively. At multivariable analysis, age (< 60 years), performance status (0 v ≥ 1), size of the largest lesion (smaller), and KIT mutation (exon 11) were significant prognostic factors for the probability of surviving beyond 10 years. Conclusion This trial was carried out on a worldwide intergroup basis, at the beginning of the learning curve of the use of imatinib, in a large population of patients with advanced GIST. With a long follow-up, 6% of patients are long-term progression free and 13% are survivors. Among clinical prognostic factors, only performance status, KIT mutation, and size of largest lesion predicted long-term outcome, likely pointing to a lower burden of disease. Genomic and/or immune profiling could help understand long-term survivorship. Addressing secondary resistance remains a therapeutic challenge.

Indexed as

AdultAgedAntineoplastic AgentsCross-Over StudiesDisease-Free SurvivalDose-Response Relationship, DrugFemaleGastrointestinal NeoplasmsGastrointestinal Stromal TumorsHumansImatinib MesylateKaplan-Meier EstimateMaleMiddle AgedNeoplasm MetastasisPrognosisAntineoplastic AgentsImatinib Mesylate

Identifiers

PMID28362562

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.